ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. (SBTX) priced its initial public offering on Dec 4, 2020 at $21.00 per share, above its $19.00–$20.00 range, raising $241.5M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $694.4M. Goldman Sachs was lead-left underwriter, joined by Leerink Partners, Stifel and H.C. Wainwright. Cooley advised the company and Latham & Watkins advised the underwriters.

At its 2020 IPO, Silverback Therapeutics (now ARS Pharmaceuticals) was a clinical-stage biopharmaceutical company with one candidate in a Phase 1/1b trial, using its ImmunoTAC platform to develop tissue-targeted therapeutics for cancer, chronic viral infections and other serious diseases.

Status

IPO

Ticker

SBTX

Exchange

Nasdaq Global Market

Priced

Dec 4, 2020

IPO price

$21.00

Price range

$19.00–$20.00

Raised

$241.5M

Market cap at IPO price

$694.4M

First filed

Nov 10, 2020

Underwriters

Goldman Sachs, Leerink Partners, Stifel and H.C. Wainwright

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.